agilon health vs Progyny
AGL and PGNY side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGL and PGNY compare
Progyny is the larger company, worth 1.5 times as much as agilon health ($2.8B against $1.9B).
Progyny grew revenue faster over the last twelve months (5.5% versus 2.0% for agilon health).
Progyny keeps more of each dollar of sales as profit, with a net margin of 6.8% compared with −1.5% at agilon health.
Progyny scores higher on the StockData Score (21 against 4 for agilon health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGL | PGNY |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $2.8B |
| Share price | $110.30 | $36.58 |
| Change, 1 year | 613% | 53.6% |
| Change, 5 years | −81.4% | −38.4% |
| Beta (5Y) | 1.26 | 1.06 |
| Employees | 856 | 856 |
| StockData Score | ||
| Total score | 4 | 21 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 6 (better) |
| Performance score | 1 | 6 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 33.6× |
| P/S | 0.3× (better) | 2.1× |
| P/B | – | 6.8× |
| EV/EBITDA | – | 19.7× |
| P/FCF | – | 15.6× |
| PEG | – | 1.14 |
| FCF yield | −0.92% | 6.4% (better) |
| Fair value | – | $37.83 |
| Margin of safety | – | 3.3% |
| Growth | ||
| Revenue growth (TTM) | 2.0% | 5.5% (better) |
| Revenue growth, 5Y average | 37.2% (better) | 30.2% |
| Net income growth (TTM) | – | 60.9% |
| EPS growth (TTM) | – | 73.0% |
| EPS growth, 5Y average | – | 6.7% |
| Profitability | ||
| Gross margin | – | 24.9% |
| Operating margin | −2.6% | 9.4% (better) |
| Net margin | −1.5% | 6.8% (better) |
| FCF margin | −0.28% | 13.4% (better) |
| Return on equity | – | 18.7% |
| Return on invested capital | – | 40.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −22.4× | – |
| Current ratio | 1.13 | 1.93 (better) |
| Altman Z-score | 2.83 | 10.01 (better) |
| Piotroski F-score | 2 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 11.2% |
| Shareholder yield | 0.00% | 11.2% (better) |
| Ownership | ||
| Held by institutions | 95.8% | 103% |
| Held by insiders | 10.1% | 2.7% |
| Insider net buying, 12 months | $300K (better) | −$14.1M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 5.6% | 6.4% |
Go deeper
- AGL stock overview
- AGL income statement
- AGL valuation and score
- PGNY stock overview
- PGNY income statement
- PGNY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.